Download MendeleyDiscovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905).
Duffey, M.O., Vos, T.J., Adams, R., Alley, J., Anthony, J., Barrett, C., Bharathan, I., Bowman, D., Bump, N.J., Chau, R., Cullis, C., Driscoll, D.L., Elder, A., Forsyth, N., Frazer, J., Guo, J., Guo, L., Hyer, M.L., Janowick, D., Kulkarni, B., Lai, S.J., Lasky, K., Li, G., Li, J., Liao, D., Little, J., Peng, B., Qian, M.G., Reynolds, D.J., Rezaei, M., Scott, M.P., Sells, T.B., Shinde, V., Shi, Q.J., Sintchak, M.D., Soucy, F., Sprott, K.T., Stroud, S.G., Nestor, M., Visiers, I., Weatherhead, G., Ye, Y., D'Amore, N.(2012) J Med Chem 55: 197-208
- PubMed: 22070629
- DOI: https://doi.org/10.1021/jm2011172
- Primary Citation of Related Structures:
3THB - PubMed Abstract:
This article describes the discovery of a series of potent inhibitors of Polo-like kinase 1 (PLK1). Optimization of this benzolactam-derived chemical series produced an orally bioavailable inhibitor of PLK1 (12c, MLN0905). In vivo pharmacokinetic-pharmacodynamic experiments demonstrated prolonged mitotic arrest after oral administration of 12c to tumor bearing nude mice. A subsequent efficacy study in nude mice achieved tumor growth inhibition or regression in a human colon tumor (HT29) xenograft model.
Organizational Affiliation:
Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States. matthew.duffey@mpi.com
